Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|||||||||||
| Income Statement [Abstract] | ||||||||||||||
| Revenues | $ 71 | $ 87 | $ 230 | $ 176 | | |||||||||
| Operating expenses: | | |||||||||||||
| Research and development expenses | (3,362) | (4,333) | (10,066) | (13,412) | | |||||||||
| Less: participation by the National Institute of Allergy and Infectious Diseases (“NIAID”), the Israeli Innovation Authority (“IIA”), Horizon Europe and other parties | 268 | 166 | 1,015 | 1,189 | | |||||||||
| Research and development expenses, net | (3,094) | (4,167) | (9,051) | (12,223) | | |||||||||
| General and administrative expenses | (2,511) | (3,020) | (7,303) | (8,655) | | | ||||||||
| Total Operating Expenses | -8699.0 | -11354.0 | -25405.0 | -33101.0 | 0 | |
||||||||
| Operating loss | (5,534) | (7,100) | (16,124) | (20,702) | | |||||||||
| Interest expenses | (218) | (217) | (648) | (623) | | | | | | | | | | |
| Other financial income (expenses), net | 362 | (441) | 1,290 | (956) | | | | | | | | | | |
| Total Other Income Expenses | -580.0 | -658.0 | -1938.0 | -1579.0 | 0.0 | |
||||||||
| Total Other Income Expenses | -144.0 | -224.0 | -642.0 | -333.0 | 0.0 | |
| |||||||
| Total Other Income Expenses | 144.0 | 224.0 | 642.0 | 333.0 | 0.0 | |
| |||||||
| Total Other Income Expenses | 580.0 | 658.0 | 1938.0 | 1579.0 | 0.0 | |
| |||||||
| Total Other Income Expenses | 144.0 | 224.0 | 642.0 | 333.0 | 0.0 | |
| |||||||
| Total Other Income Expenses | -144.0 | -224.0 | -642.0 | -333.0 | 0.0 | |
| |||||||
| Total Other Income Expenses | -580.0 | -658.0 | -1938.0 | -1579.0 | 0.0 | |
| |||||||
| Total Other Income Expenses | 580.0 | 658.0 | 1938.0 | 1579.0 | 0.0 | |
| |||||||
| Total financial income (expenses), net | 144 | (658) | 642 | (1,579) | | | | |||||||
| Total Other Income Expenses | 288.0 | -1316.0 | 1284.0 | -3158.0 | 0.0 | |
||||||||
| Net loss | (5,390) | (7,758) | (15,482) | (22,281) | | | ||||||||
| Net loss attributed to non-controlling interest | (97) | (134) | (323) | (419) | ||||||||||
| Net loss attributed to shareholders | $ (5,293) | $ (7,624) | $ (15,159) | $ (21,862) | ||||||||||
| Loss per share: | ||||||||||||||
| Basic net loss per share (in Dollars per share) | $ (1.01) | $ (1.52) | $ (2.92) | $ (5.04) | ||||||||||
| Weighted average number of shares used in computing basic net loss per share (in Shares) | [1] | 5,221,162 | 4,993,451 | 5,193,808 | 4,402,130 | |||||||||
| ||||||||||||||
| X | ||||||||||
- Definition Grants received from the government and third parties for research and development programs. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of research and development expenses. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. No definition available.
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|